Evolution of the Average Target: Integra LifeSciences Holdings Corporation

Evolution of the Average Target - Integra LifeSciences Holdings Corporation

Evolution of the Target Price: Integra LifeSciences Holdings Corporation

Evolution of the Target Price - Integra LifeSciences Holdings Corporation

Changes in Analyst Recommendations: Integra LifeSciences Holdings Corporation

8a455b95.5yNzdYScUeUQTmLXSf63z14LEzjr48_ZLMnHx_0lnIo.nxEmJNbXKJZZPhWUDKHc-gxoek-ezqqAQLmU97lsqNWdbhQxzakVtUQ9Ow~5d59aa7e636181973dbded258eea7790
10-27 UBS Adjusts Integra LifeSciences Price Target to $14 From $19, Maintains Neutral Rating MT
10-23 Truist Adjusts Price Target on Integra LifeSciences to $13 From $15, Maintains Hold Rating MT
10-14 Truist Securities Adjusts Integra LifeSciences Price Target to $15 From $19 MT
07-30 BMO Cuts Price Target on Integra LifeSciences Holdings to $18 From $19, Keeps Market Perform Rating MT
07-28 UBS Initiates Coverage on Integra LifeSciences With Neutral Rating, $19 Price Target MT
07-16 Truist Adjusts Price Target on Integra LifeSciences Holdings to $19 From $14, Maintains Hold Rating MT
07-09 BMO Capital Initiates Integra LifeSciences at Market Perform With $19 Price Target MT
06-19 Integra LifeSciences Shares Rise After Upgrade From Argus Research MT
06-18 Argus Research Upgrades Integra LifeSciences to Buy From Hold, $25 Price Target MT
05-28 Citigroup Upgrades Integra LifeSciences to Neutral From Sell, Adjusts Price Target to $16 From $11 MT
05-06 Truist Adjusts Price Target on Integra LifeSciences to $14 From $12, Maintains Hold Rating MT
04-15 Truist Cuts Price Target on Integra LifeSciences Holdings to $12 From $13, Keeps Hold Rating MT
01-12 Canaccord Genuity Initiates Coverage on Integra LifeSciences With Speculative Buy Rating, CA$9.25 Price Target MT
31/07/25 Medtech firm Integra's Q2 revenue beats expectations RE
13/05/25 Morgan Stanley Adjusts Price Target on Integra LifeSciences Holdings to $10 From $20, Maintains Equalweight Rating MT
06/05/25 Top Midday Decliners MT
11/04/25 Truist Cuts Price Target on Integra LifeSciences Holdings to $19 From $26, Keeps Hold Rating MT
31/03/25 Argus Upgrades Integra LifeSciences to Buy From Hold, Price Target is $28 MT
06/11/24 Truist Raises Price Target on Integra LifeSciences Holdings to $26 From $21, Keeps Hold Rating MT
14/10/24 Correction: Truist Trims Price Target on Integra LifeSciences Holdings to $21 From $26, Keeps Hold Rating MT
14/10/24 Truist Raises Price Target on Integra LifeSciences Holdings to $26 From $21, Keeps Hold Rating MT
07/10/24 BTIG Upgrades Integra LifeSciences Holdings to Neutral From Sell MT
30/07/24 BTIG Downgrades Integra LifeSciences Holdings to Sell From Neutral, Price Target is $22 MT
30/07/24 Citigroup Downgrades Integra LifeSciences Holdings to Sell From Neutral, Adjusts Price Target to $23 From $30 MT
30/07/24 Analyst recommendations: 3M Company, Aon, Murphy USA, Skyworks, Tesla... Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+28%
+15.47%
+19.28%
+10.38%
+21.5%
+13.79%
+15.94%
+0.21%
+23.36%
+29.76%
Average +17.77%
Weighted average by Cap. +15.94%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
12.24USD
Average target price
15.67USD
Spread / Average Target
+28.00%
High Price Target
23.00USD
Spread / Highest target
+87.91%
Low Price Target
13.00USD
Spread / Lowest Target
+6.21%

Analyst Consensus Detail

Analyst consensus - Integra LifeSciences Holdings Corporation

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Integra LifeSciences Holdings Corporation
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Integra LifeSciences Holdings Corporation
  1. Stock Market
  2. Stocks
  3. IART Stock
  4. Consensus Integra LifeSciences Holdings Corporation